Updated time: 2021-08-24 10:24:13
Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) antagonistic antibody could effective inhibit tumor growth and humanized CTLA-4 antibodies, Ipilimumab also known as Yervoy was already approved by FDA (US Food and Drug Administration) and sold in 120000 USD for a course of treatment. In this report, we have identified a DNA aptamer, called CA21, which effectively inhibit CTLA-4 function. Moreover, CA21 are lower molecular weight that allows it easier to penetrate through tissue than antibody, low cost in chemical synthesis, easily modified and highly stabilized. All in all, CTLA-4 antagonistic aptamers hold a great potential as a new drug for cancer and immune therapy.
- There are several antagonistic CTLA-4 antibodies on the market, such as tremelimumab and ipilimumab. These antibodies had significant effect in treatment of multiple types of cancers. However, antibodies are expensive, highly immunogenic and relatively unstable to environmental stress. These disadvantages have largely limited its application.
- On the other hand, aptamer has no these kinds of disadvantages and, moreover, easy to be chemical modified for variable application.
- One RNA aptamer has been published in 2003. However, this RNA aptamer have several weaknesses as below: (1) RNA is very unstable and need to incorporate modified RNA bases which are expensive. Our system is DNA aptamer which is much cheaper. (2) The working concentration of their RNA aptamer is about 200-400nM which is not good. (3) The therapeutic result seems insignificant in their data.
- Our CA21 aptamer are high affinity DNA aptamer which require only 10nM of aptamer treatment in animal studies and the results are significant both in tumor growth inhibition or survival curve.
12A-1030616
US 10533179 B2、TW I604846、JP 6702938、EP 3174984
- Cancer therapy.
- Immunotherapy
- Immune associated disease therapy.
Pan-Chyr Yang, Konan Peck, Yi-Chung Chang, Bo-Tsang Huang, Shauh-Der Yeh
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Antagonistic CTLA-4 aptamers and applications thereof in enhancing immune activity